Skip to search formSkip to main contentSkip to account menu

zabicipril

Known as: (3S)-2-((2S)-N-((1S)-1-Carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic Acid, 1-ethyl Ester, 2-(N-(1-carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic acid 1-ethyl ester 
A non-thiol angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, zabicipril is rapidly converted in vivo by de… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Bridged Bicyclo Compounds, Heterocyclic

Narrower (1)

S 9650

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men
SummaryZabicipril is a recently introduced angiotensin converting enzyme (ACE) inhibitor, which has been observed in experimental… 
1998
1998
The arterial length‐densities under preventive angiotensin‐converting‐enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats
Abstract The length density (LV) of capillaries is known to be increased in the hearts of spontaneously hypertensive rats (SHR… 
1998
1998
Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.
AIMS To investigate, in healthy volunteers, the relationships between the plasma concentrations (C, ng ml(-1)) of zabiciprilat… 
1994
1994
Angiotensin‐Converting Enzyme Inhibition Increases Exercise Tolerance and Muscle Blood Flow in Rats with Peripheral Arterial Insufficiency
To determine the effect of angiotensin‐converting enzyme (ACE) inhibition on exercise tolerance and muscle blood flow (BF) to… 
1993
1993
Vascular remodeling in systemic hypertension.
1993
1993
Enzyme Immunoassays for a New Angiotensin‐Converting Enzyme Inhibitor, Zabicipril, and Its Active Metabolite in Human Plasma: Application to Pharmacokinetic Studies
Zabicipril (S 9650) is a new angiotensin-converting enzyme inhibitor whose hydrolysis in vivo produces the pharmacologically… 
1992
1992
Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses
Aim We performed two sets of experiments in order to prevent or to regress cardiac and vascular hypertrophy, using… 
1992
1992
Radioimmunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite, zabiciprilat, in human plasma.
Zabicipril (Z), a new angiotensin-converting-enzyme inhibitor under development, is a prodrug that has to be deesterified in vivo… 
1990
1990
Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
1. Zabicipril, S9650, a new angiotensin converting enzyme inhibitor, was administered to salt-replete, normotensive males in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)